

## ***PATRICK COMER COURAGE FOUNDATION***

### **UMASS PANCREATIC CANCER CLINICAL TRIALS**

January 29<sup>th</sup>, 2009

Clinical trials play a crucial role in advancing cutting edge therapy for pancreatic cancer patients. To increase the number of clinical trials available at UMass, Dr. Bilal Piperdi has joined the Pancreatic Cancer Research Team (PCRT).

PCRT is a group of imminent investigators dedicated to organizing and accelerating the clinical development of new agents for the treatment of patients with pancreatic cancer. The group shares a passion to bring new advances to patients with pancreatic cancer as rapidly as possible. PCRT provides the only coordinated effort in the world dedicated to rapidly translating research discoveries into new treatments and supportive care for patients with pancreatic cancer. PCRT facilitates Phase I through Phase III clinical trials, with an emphasis on Phase I/II and Phase II trials.

This dedicated pancreatic cancer clinical trials program is generously supported by the Pancreatic Cancer Alliance, an all volunteer organization committed to increasing research for pancreatic cancer.



Jim Comer, a member of the Pancreatic Cancer Alliance, is shown presenting Dr. Walter H. Ettinger, MD, MBA, President, UMass Memorial Medical Center, Associate Provost Clinical and Population Research, University of Massachusetts Medical School, a check from the Patrick Comer Courage Foundation to support these clinical trials.